Chris Scotti

For Corporates
Insights into Healthcare M&A: Q3 2024 Trends
Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Related Team
Chris Scotti

Chris Scotti is a Senior Managing Director of Institutional Equities at Leerink Partners.

Prior to joining Leerink Partners in 2024, Mr. Scotti served as an Executive Director at Morgan Stanley, Institutional Sales division. Mr. Scotti built up a significant franchise in the Biotech and MedTech verticals with both public and private Healthcare investors which dates back over 20 years. During his tenure at Morgan Stanley, he led and supported several prime brokerage mandates and swap relationships in the healthcare sector.

Working closely with the Healthcare Investment Banking and Capital Markets origination and execution teams, he has built extensive relationships with his clients and was a key contributor to the TTW and IPO process, which led to Morgan Stanley’s top ranking in the League tables for the last 15 years. Prior to his role at Morgan Stanley, Mr. Scotti spent 10 years at UBS running a hybrid business covering Institutional investors along with high-net-worth individuals. He began his career in Finance as a Vice-President at Gabelli & Company.

Mr. Scotti earned his Bachelor’s degree in Finance with a minor in Marketing from the University of Rhode Island and was a four year letterman with the Basketball team. He received his M.B.A. in Finance from Fordham University.

Partner With Us

Contact Us